1. Home
  2. SKYE vs YQ Comparison

SKYE vs YQ Comparison

Compare SKYE & YQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.79

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

YQ

17 Education & Technology Group Inc.

HOLD

Current Price

$1.84

Market Cap

22.7M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
YQ
Founded
2012
2012
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
22.7M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
SKYE
YQ
Price
$0.79
$1.84
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
191.2K
5.9K
Earning Date
05-07-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$1.51
52 Week High
$5.75
$6.45

Technical Indicators

Market Signals
Indicator
SKYE
YQ
Relative Strength Index (RSI) 58.41 40.32
Support Level $0.68 $1.78
Resistance Level $0.83 $2.09
Average True Range (ATR) 0.06 0.19
MACD 0.02 0.05
Stochastic Oscillator 80.70 42.86

Price Performance

Historical Comparison
SKYE
YQ

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

Share on Social Networks: